- Record quarterly revenue of $76.9 million, up 18% QoQ and up 619% YoY
- Multiple secular trends, design wins across diverse AI platform architectures, and increasing average dollar content position the Company to outpace industry growth
SANTA CLARA, CA, U.S. – August 6, 2024 – Astera Labs, Inc. (Nasdaq: ALAB), a global leader in semiconductor-based connectivity solutions for cloud and AI infrastructure, today announced preliminary financial results for the second quarter of fiscal 2024, ended June 30, 2024.
“Astera Labs achieved robust top-line growth during Q2, and we expect even stronger sequential growth in the September quarter, fueled by the production ramp of new AI platforms at hyperscalers featuring both third-party and internally developed accelerators,” said Jitendra Mohan, Astera Labs’ Chief Executive Officer. “Sustained secular trends in AI adoption, design wins across diverse AI platform architectures, and increasing average dollar content in next generation GPU-based AI platforms give us confidence in our ability to outperform industry growth rates. Our close collaboration with hyperscalers and AI platform providers continues to yield valuable insights, unlocking new product and business opportunities for our Intelligent Connectivity Platform, which we believe will drive strong, long-term growth.”
Second Quarter of Fiscal 2024 Financial Highlights
GAAP Financial Results:
- Revenue of $76.9 million, up 18% sequentially and up 619% year-over-year
- GAAP gross margin of 77.9%
- GAAP operating loss of $24.3 million
- GAAP net loss of $7.5 million
- GAAP diluted net loss per share of $0.05
Non-GAAP Financial Results (excluding the impact of stock-based compensation expense and the income tax effects of non-GAAP adjustments):
- Non-GAAP gross margin of 78.0%
- Non-GAAP operating income of $18.7 million
- Non-GAAP net income of $22.2 million
- Non-GAAP diluted earnings per share of $0.13
Second Quarter of Fiscal 2024 and Recent Business Highlights
- Demonstrated the industry’s first end-to-end PCIe optical connectivity link to provide extended reach for larger, disaggregated GPU clusters. PCIe over optics expands Astera Labs’ widely deployed and field-tested Aries family of Smart DSP retimers and Smart Cable Modules (SCMs) to deliver robust PCIe and CXL connectivity in chip-to-chip, box-to-box, and rack-to-rack topologies throughout the data center.
- Announced the expansion of PCIe 6.x testing capabilities with a new Cloud-Scale Interop Lab in Taiwan, accelerating time-to-market for PCIe 6.x AI servers optimized with the recently launched Aries 6 Smart DSP retimers. The new Interop Lab will facilitate closer collaboration with key ODM customers to test Aries 6 in complex PCIe topologies with a broad variety of hosts and endpoints interconnected over varying channel insertion loss budgets in real systems.
- Announced the intention to expand operations into India with a new R&D site to further scale the organization and strengthen the Company’s global footprint. The new site will open in Bangalore later this year and we believe it will help to attract the region’s rich engineering talent and resources to support the next phase of growth for Astera Labs.
- Appointed Bethany Mayer to the Board of Directors, bringing over 30 years of experience as a visionary leader and board member across multiple networking, cybersecurity, and semiconductor companies.
Third Quarter of Fiscal 2024 Financial Outlook
Based on current business trends and conditions, we estimate the following:
GAAP Financial Outlook:
- Revenue within a range of $95 million to $100 million
- GAAP gross margin of approximately 75%
- GAAP operating expenses of within a range of approximately $92 million to $93 million
- GAAP tax rate of approximately (22%)
- GAAP diluted loss per share within a range of approximately $0.06 to $0.08 on weighted-average diluted shares outstanding of approximately 155 million
Non-GAAP Financial Outlook (excluding the impact of approximately $46 million of stock-based compensation and including $5.5 million of additional income taxes):
- Non-GAAP gross margin of approximately 75%
- Non-GAAP operating expenses within a range of approximately $46 million to $47 million
- Non-GAAP tax rate of approximately 20%
- Non-GAAP diluted earnings per share within a range of approximately $0.16 to $0.17 on weighted-average diluted shares outstanding of approximately 177 million
Earnings Webcast and Conference Call
Astera Labs will host a conference call to review its financial results for the second quarter of fiscal 2024 and to discuss our financial outlook today at 1:30 p.m. Pacific Time. Interested parties may join the conference call by dialing 1-800-715-9871 and using conference ID 8761024. The call will also be webcast and can be accessed at the Astera Labs website at https://ir.asteralabs.com/. The webcast will be recorded and available for replay on our website for the next six months.
Discussion of Non-GAAP Financial Measures
We use certain non-GAAP financial measures to supplement the performance measures in our consolidated financial statements, which are presented in accordance with GAAP. A reconciliation of these non-GAAP measures to the closest GAAP measure can be found later in this release. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP tax rate, non-GAAP net income (loss), non-GAAP diluted earnings (loss) per share, and non-GAAP weighted-average share count. We use these non-GAAP financial measures for financial and operational decision-making and as a means to assist us in evaluating period-to-period comparisons. By excluding certain items that may not be indicative of our recurring core operating results, we believe that, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP tax rate, non-GAAP net income (loss), pro forma non-GAAP diluted earnings (loss) per share, and pro forma non-GAAP weighted-average share count provide meaningful supplemental information regarding our performance. Accordingly, we believe these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by our institutional investors and the analyst community to help them analyze the health of our business. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures. No reconciliation is provided with respect to the forward-looking non-GAAP financial measures included in our non-GAAP financial outlook, as the GAAP measures are not accessible on a forward-looking basis. As a result, we cannot reliably predict all necessary components or their impact to reconcile such financial measures without unreasonable effort. The events necessitating a non-GAAP adjustment are inherently unpredictable and may have a significant impact on our future GAAP financial results.
We adjust the following items from one or more of our non-GAAP financial measures:
Stock-based compensation expense
We exclude stock-based compensation expense, which is a non-cash expense, from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, companies calculate non-cash stock-based compensation expense using a variety of valuation methodologies and subjective assumptions. Moreover, stock-based compensation expense is a non-cash charge that can vary significantly from period to period for reasons that are unrelated to our core operating performance, and therefore excluding this item provides investors and other users of our financial information with information that allows meaningful comparison of our business performance across periods.
Employer payroll taxes related to stock-based compensation resulting from our IPO
We exclude employer payroll taxes related to the time-based vesting and net settlement of restricted stock units in connection with our initial public offering (the “IPO”), because this does not correlate to the operation of our business. We believe that excluding this item provides meaningful supplemental information regarding operational performance given the amount of employer payroll tax-related items on employee stock transactions was immaterial prior to our IPO.
Income Tax effect
This represents the impact of the non-GAAP adjustments on an after-tax basis in connection with the presentation of non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share. This approach is designed to enhance investors’ ability to understand the impact of our non-GAAP tax expense on its current operations, provide improved modeling accuracy, and substantially reduce fluctuations caused by GAAP to non-GAAP adjustments.
Pro-forma non-GAAP weighted-average shares to compute non-GAAP net income (loss)
We present pro-forma non-GAAP weighted-average shares, assuming the redeemable convertible preferred stock is converted from the beginning of each respective periods presented, to provide meaningful supplemental information regarding EPS trend on a consistent basis. All of our outstanding redeemable preferred stock converted into the equivalent number of shares of common stock in connection with our IPO.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements based on Astera Labs’ current expectations. The words “believe”, “estimate”, “expect”, “intend”, “anticipate”, “plan”, “project”, “will”, and similar phrases as they relate to Astera Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Astera Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our business strategy and plans, our objectives for future operations, including the success of our global footprint expansion, our development or delivery of new or enhanced products and anticipated results of those products for our customers, our competitive positioning, technological capabilities and plans, and macroeconomic trends in cloud and AI infrastructure. A variety of risks and factors that are beyond our control could cause actual results to differ materially from those in the forward-looking statements including, without limitation: the competitive and cyclical nature of the semiconductor industry; the concentration of our customer base; the continued demand for AI; the challenging macroeconomic environment, including disruptions in the financial services industry; risks that demand and the supply chain may be adversely affected, including by military conflict (such as between Russia/Ukraine and Israel/Hamas), terrorism, sanctions or other geopolitical events globally (including conflict between Taiwan and China); quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with managing international activities (including trade barriers, particularly with respect to China); absence of long-term commitments from customers; risks that Astera Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; stock price volatility; information technology risks, including cyber-attacks against Astera Labs’ products and its networks; and other risks and uncertainties that are detailed under the caption “Risk Factors” and elsewhere in our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) and the other SEC filings and reports Astera Labs may make from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor(s) may cause actual results or outcomes to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not rely on any of the forward-looking statements. Astera Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
ASTERA LABS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(In thousands)
| June 30, 2024 | December 31, 2023 | |||
| Assets | ||||
| Current assets | ||||
| Cash and cash equivalents | $ 421,076 | $ 45,098 | ||
| Marketable securities | 409,919 | 104,215 | ||
| Accounts receivable, net | 22,233 | 8,335 | ||
| Inventory | 28,572 | 24,095 | ||
| Prepaid expenses and other current assets | 9,445 | 4,064 | ||
| Total current assets | 891,245 | 185,807 | ||
| Property and equipment, net | 21,821 | 4,712 | ||
| Other assets | 2,449 | 5,773 | ||
| Total assets | $ 915,515 | $ 196,292 | ||
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||||
| Current liabilities | ||||
| Accounts payable | $ 14,595 | $ 6,337 | ||
| Accrued expenses and other current liabilities | 49,478 | 28,742 | ||
| Total current liabilities | 64,073 | 35,079 | ||
| Other liabilities | 6,190 | 3,787 | ||
| Total liabilities | 70,263 | 38,866 | ||
| Commitments and contingencies | ||||
| Redeemable convertible preferred stock | — | 255,127 | ||
| Stockholders’ equity (deficit) | ||||
| Common stock | 16 | 4 | ||
| Additional paid-in capital | 1,071,504 | 27,411 | ||
| Accumulated other comprehensive (loss) income | (352) | 259 | ||
| Accumulated deficit | (225,916) | (125,375) | ||
| Total stockholders’ equity (deficit) | 845,252 | (97,701) | ||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $ 915,515 | $ 196,292 |
ASTERA LABS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In thousands, except per share amounts)
| Three Months Ended | Six Months Ended | |||||||||
| June 30, 2024 | March 31, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||
| Revenue | $ 76,850 | $ 65,258 | $ 10,688 | $ 142,108 | $ 28,352 | |||||
| Cost of revenue | 16,996 | 14,738 | 2,249 | 31,734 | 15,655 | |||||
| Gross profit | 59,854 | 50,520 | 8,439 | 110,374 | 12,697 | |||||
| Operating expenses | ||||||||||
| Research and development | 40,089 | 53,558 | 17,860 | 93,647 | 33,127 | |||||
| Sales and marketing | 22,076 | 55,510 | 5,097 | 77,586 | 9,490 | |||||
| General and administrative | 22,036 | 24,419 | 3,095 | 46,455 | 6,620 | |||||
| Total operating expenses | 84,201 | 133,487 | 26,052 | 217,688 | 49,237 | |||||
| Operating loss | (24,347) | (82,967) | (17,613) | (107,314) | (36,540) | |||||
| Interest income | 10,264 | 2,554 | 1,555 | 12,818 | 3,151 | |||||
| Loss before income taxes | (14,083) | (80,413) | (16,058) | (94,496) | (33,389) | |||||
| Income tax (benefit) provision | (6,537) | 12,582 | 3,946 | 6,045 | 4,069 | |||||
| Net loss | $ (7,546) | $ (92,995) | $ (20,004) | $ (100,541) | $ (37,458) | |||||
| Net loss per share attributable to common stockholders: | ||||||||||
| Basic and diluted | $ (0.05) | $ (1.77) | $ (0.55) | $ (0.97) | $ (1.03) | |||||
| Weighted-average shares used in calculating net loss per share attributable to common stockholders: | ||||||||||
| Basic and diluted | 155,199 | 52,532 | 36,567 | 103,865 | 36,199 | |||||
ASTERA LABS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(In thousands)
| Six Months Ended | ||||
| June 30, 2024 | June 30, 2023 | |||
| Cash flows from operating activities | ||||
| Net loss | $ (100,541) | $ (37,458) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||||
| Stock-based compensation | 140,835 | 4,669 | ||
| Inventory write-downs | 1,493 | 9,733 | ||
| Depreciation | 1,331 | 763 | ||
| Non-cash operating lease expense | 1,106 | 536 | ||
| Warrants contra revenue | 443 | 127 | ||
| Accretion of discounts on marketable securities | (1,637) | (640) | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable, net | (13,898) | 9,081 | ||
| Inventory | (5,970) | 1,374 | ||
| Prepaid expenses and other assets | (5,396) | 223 | ||
| Accounts payable | 5,831 | (7,745) | ||
| Accrued expenses and other liabilities | 10,930 | (6,844) | ||
| Operating lease liability | (1,062) | (600) | ||
| Net cash provided by (used in) operating activities | 33,465 | (26,781) | ||
| Cash flows from investing activities | ||||
| Purchases of property and equipment | (2,100) | (1,014) | ||
| Purchases of marketable securities | (345,756) | (27,274) | ||
| Maturities of marketable securities | 20,776 | 18,000 | ||
| Sales of marketable securities | 20,358 | 54,749 | ||
| Net cash (used in) provided by investing activities | (306,722) | 44,461 | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | 672,198 | — | ||
| Payment of deferred offering costs | (4,801) | — | ||
| Tax withholding related to net share settlements of restricted stock units | (20,111) | — | ||
| Proceeds (payments) from exercises of stock options, net of repurchases | 1,949 | (87) | ||
| Net cash provided by (used in) financing activities | 649,235 | (87) | ||
| Net increase in cash and cash equivalents | 375,978 | 17,593 | ||
| Cash and cash equivalents | ||||
| Beginning of the period | 45,098 | 76,088 | ||
| End of the period | $ 421,076 | $ 93,681 | ||
ASTERA LABS, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (Unaudited)
(In thousands, except percentages and per share amounts)
| Three Months Ended | Six Months Ended | |||||||||
| June 30, 2024 | March 31, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||
| GAAP gross profit | $ 59,854 | $ 50,520 | $ 8,439 | $ 110,374 | $ 12,697 | |||||
| Stock-based compensation expense upon IPO (1) | — | 516 | — | 516 | — | |||||
| Stock-based compensation expense | 84 | 12 | 2 | 96 | 7 | |||||
| Non-GAAP gross profit | $ 59,938 | $ 51,048 | $ 8,441 | $ 110,986 | $ 12,704 | |||||
| GAAP gross margin | 77.9 % | 77.4 % | 79.0 % | 77.7 % | 44.8 % | |||||
| Stock-based compensation expense upon IPO (1) | — | 0.8 | — | 0.3 | — | |||||
| Stock-based compensation expense | 0.1 | — | — | 0.1 | — | |||||
| Non-GAAP gross margin | 78.0 % | 78.2 % | 79.0 % | 78.1 % | 44.8 % | |||||
| GAAP operating loss | $ (24,347) | $ (82,967) | $ (17,613) | $ (107,314) | $ (36,540) | |||||
| Stock-based compensation expense upon IPO (1) | — | 88,873 | — | 88,873 | — | |||||
| Stock-based compensation expense | 43,067 | 8,895 | 2,672 | 51,962 | 4,669 | |||||
| Employer payroll tax related to stock-based compensation from IPO (2) | — | 1,072 | — | 1,072 | — | |||||
| Non-GAAP operating income (loss) | $ 18,720 | $ 15,873 | $ (14,941) | $ 34,593 | $ (31,871) | |||||
| GAAP net loss | $ (7,546) | $ (92,995) | $ (20,004) | $ (100,541) | $ (37,458) | |||||
| Stock-based compensation expense upon IPO (1) | — | 88,873 | — | 88,873 | — | |||||
| Stock-based compensation expense | 43,067 | 8,895 | 2,672 | 51,962 | 4,669 | |||||
| Employer payroll tax related to stock-based compensation from IPO (2) | — | 1,072 | — | 1,072 | — | |||||
| Income tax effect (3) | (13,296) | 8,485 | — | (4,811) | — | |||||
| Non-GAAP net income (loss) | $ 22,225 | $ 14,330 | $ (17,332) | $ 36,555 | $ (32,789) | |||||
| Net (loss) income per share attributable to common stockholders: | ||||||||||
| GAAP – basic and diluted | $ (0.05) | $ (1.77) | $ (0.55) | $ (0.97) | $ (1.03) | |||||
| Pro forma Non-GAAP – diluted | $ 0.13 | $ 0.10 | $ (0.14) | $ 0.23 | $ (0.26) | |||||
| Weighted average shares used to compute net loss per share attributable to common stockholders: | ||||||||||
| GAAP – basic and diluted | 155,199 | 52,532 | 36,567 | 103,865 | 36,199 | |||||
| Pro forma Non-GAAP – diluted (4) | 175,279 | 147,514 | 127,458 | 162,378 | 127,090 | |||||
____________________
(1) Stock-based compensation expense recognized in connection with the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.
(2) Employer payroll taxes related to the time-based vesting and settlement of RSUs, that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.
(3) The income tax effect represents the impact of the non-GAAP adjustments on an after-tax basis in connection with the presentation of non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share. For the three months ended June 30, 2024 and March 31, 2024, the non-GAAP tax rates were approximately of 23% and 22%, respectively. For the six months ended June 30, 2024, the non-GAAP tax rate was approximately 23%. The adjustments for the three and six months ended June 30, 2023 were not material.
(4) We present the pro-forma non-GAAP weighted average shares to provide meaningful supplemental information of comparable shares for each periods presented. The pro forma weighted average shares is calculated as follows:
| Three Months Ended | Six Months Ended | |||||||||
| June 30, 2024 | March 31, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | ||||||
| Shares used to compute GAAP net loss per share attributable to common stockholders – diluted | 155,199 | 52,532 | 36,567 | 103,865 | 36,199 | |||||
| Weighted average effect of the assumed conversion of redeemable convertible preferred stock from the beginning of the periods | — | 78,905 | 90,891 | 40,451 | 90,891 | |||||
| Effect of dilutive equivalent shares | 20,080 | 16,077 | — | 18,062 | — | |||||
| Shares used to compute pro forma non-GAAP net income (loss) per share- diluted | 175,279 | 147,514 | 127,458 | 162,378 | 127,090 | |||||
ASTERA LABS, INC.
SUPPLEMENTAL FINANCIAL INFORMATION
STOCK-BASED COMPENSATION EXPENSE (Unaudited)
(In thousands)
| Three Months Ended | Six Months Ended | ||||||||
| June 30, 2024 | March 31, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | |||||
| Cost of revenue | $ 84 | $ 528 | $ 2 | $ 612 | $ 7 | ||||
| Research and development | 12,971 | 30,007 | 1,672 | 42,978 | 3,351 | ||||
| Sales and marketing | 15,758 | 49,258 | 694 | 65,016 | 695 | ||||
| General and administrative | 14,254 | 17,975 | 304 | 32,229 | 616 | ||||
| Total stock-based compensation expense (1) | $ 43,067 | $ 97,768 | $ 2,672 | $ 140,835 | $ 4,669 | ||||
____________________
(1) Stock-based compensation expense recognized during the three months ended March 31, 2024 and six months ended June 30, 2024 included $88.9 million of cumulative stock-based compensation expense related to the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.
IR CONTACT: Leslie Green